Production of Therapeutic Glycoproteins - Key Players, Innovators and Industry Analysis

8/3/2019 Production of Therapeutic Glycoproteins - Key Players, Innovators and Industry Analysis

1/25

Production of TherapeuticGlycoproteinsKnowledge ServicesKnowledge Services

[email protected] Production of TherapeuticGlycoproteins


2/25

Like this presentation?

Buy the customized report from Dolcera

Patent Analytics Services Market Research Services Purchase Patent Dashboard

Patent Landscape Services Dolcera Processes Industry FocusPatent Search Services Patent Alerting Services Dolcera Tools

2

This is only a sample report with brief analysis. Purchase the complete

report here. Price: $999

Dolcera can provide a comprehensive report customized to your needs

Samir Raiyani

Email:[email protected]

Phone: +1-650-425-6772

Fax: +1-866-690-7517

Production of TherapeuticGlycoproteins

[email protected]


3/25

Production ofTherapeutic Glycoproteins

Introduction

IP search

Taxonomy

Top Cited Patents

Patent to product mapping

Key Findings

Major Players

IP Activity

Geographical Activity

Categorization on the basis of production

method - Top assignees under each categoryTechnology citation statistics

Assignee citation statistics

Contents

3Production of TherapeuticGlycoproteins

[email protected]


4/25

Introduction

Glycosylation is the attachment of a carbohydrate group to a protein, catalyzed by

enzymes called glycosyl transferases.

The majority of clinically approved protein drugs bear some form of post-

translational modification, most commonly glycosylation.

Glycosylation is important because it can influence the therapeutic efficacy,

immunogenicity, solubility, and in-vivo half life of the glycoprotein.

Glycosylation has been found to occur in a large variety of protein classes,including but not limited to antibodies, protein hormones, growth factors,

cytokines and vaccines.

Several systems used for the production of proteins in glycosylated form are being

explored. Some of these include Mammalian systems like CHO, fungal systems,

insects, plants, bacterial systems etc. Glycosylated proteins are also being

produced by in vitro means.

4Production of TherapeuticGlycoproteins

[email protected]


5/25

Taxonomy

5

A detailed taxonomy is

presented, which was

obtained after a sample

analysis. It includes

various hosts, systems,process and utilities of

protein glycosylation

To see the detailed VVT Taxonomy, mailto: [email protected]


[email protected]


6/25

Classification

6

Different classes related to glycosylated therapeutics and production of

therapeutics that can be glycosylated are identified.

These Classes are used in the search strategy

To see the detailed classification, mailto: [email protected]


[email protected]


7/25

Control Patents

7

Highly relevant patents are used for extracting keywords and ensuring the

quality of the search query

To see the detailed table, mailto: [email protected]

Production of [email protected]


8/25

Search Concepts

8

Concepts used to search patent literature

Relevant keywords were also translated to French and German tosearch for French and German language patents




9/25

IP Search

9

Database: Thomson Innovation

Timeline: 01-01-1991 to 30-08-2011




10/25

Patent to product mapping

The patens are mapped to the products based on patent focus

Production of TherapeuticGlycoproteins [email protected]


11/25

Dolcera Dashboard

Dolcera dashboard is a web 2.0 technology. It enables dynamic

presentation of patent data



12/25

Insights: Major Players

Roche Holding Ltd, Kirin Holdings Company Limited and Novo Nordisk are the top

assignees in the field

12Production of [email protected]


13/25

Insights: Key Patents

The key patents in the area are held by University of California, University of

Texas, Alko Inc and Bristol-Myers Squibb Co.

13



14/25

Insights: Year wise IP activity

Year wise IP activity based on publication years



15/25

Insights: Year wise IP activity

15

Year wise IP activity based on priority years



16/25

Insights: Geographical Distribution

Geographical distribution of patents



17/25

Insights: Major Player Mammalian cell lines

Roche holding Ltd., Kirin Holdings Co.Ltd. and Lonza Group AG are active in using

mammalian cell lines



18/25

Insights: Major Player Transgenic Animals

Abbott Lab. Leads in using transgenic animals

Production of Therapeutic

Glycoproteins

[email protected]


19/25

Insights: Major Player - Plants

Dow Chemical Co. and Plant Research International lead in plant systems


Glycoproteins

[email protected]


20/25

Insights: Major Player - Microorganisms

Merck & Co. Inc, Kirin Holdings Co. Ltd. and Novozymes AS lead in microbial

systems


Glycoproteins

[email protected]


21/25

Insights: Major Player - Enzymes

Novo Nordisk, Kirin Holdings Co.Ltd. and Roche Holding Ltd. lead in using enzyme

systems


Glycoproteins

[email protected]


22/25

Insights: Major Player Chemical/Cell free synthesis

Novo Nordisk, Roche Holding Ltd. and Otsuka Holding Co. Ltd. lead in

chemical/cell free synthesis systems


Glycoproteins

[email protected]


23/25

Insights: Major Player: Fermentation/Culture conditions

Roche Holding Ltd., Pfizer Inc. and Bristol Myers Squibb Co. lead in

fermentation/culture conditions


Glycoproteins

[email protected]


24/25

Conclusions

24

The first generation of biopharmaceuticals manufactured using recombinant

technologies was launched in the 1980s, and patents protecting them are now nearing

expiration. As with small molecule drugs, the expiration of patents creates an

opportunity for generic biologicals to enter the market. Current IP situation allows a

new patent protection of the product and the process

CHO is the most preferred system for production of proteins with mammalian type

glycosylation.

Due to drawbacks in mammalian systems, active research is on to find alternate

production systems for producing glycoproteins. Few such hosts include E.coli, Yeast,

Fungi, plants and insect systems. A few patents also talk on chemical/cell free synthesis for in vitro protein glycosylation.


Glycoproteins

[email protected]


25/25

Like this presentation?

Buy the customized report from Dolcera

Patent Analytics Services Market Research Services Purchase Patent Dashboard

Patent Landscape Services Dolcera Processes Industry FocusPatent Search Services Patent Alerting Services Dolcera Tools

25

This is only a sample report with brief analysis. Purchase the complete

report here. Price: $999

Dolcera can provide a comprehensive report customized to your needs

Samir Raiyani

Email:[email protected]

Phone: +1-650-425-6772Fax: +1-866-690-7517


Glycoproteins

[email protected]

Production of Therapeutic Glycoproteins - Key Players, Innovators and Industry Analysis

Documents

Transcript of Production of Therapeutic Glycoproteins - Key Players, Innovators and Industry Analysis